Back to results
US 7,591,994 B2Granted
Camptothecin-binding moiety conjugates
AssigneeImmunomedics, Inc.
InventorsSerengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
Life of this patent
Estimating the term…
Abstract
The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
Claims14
A conjugate of a camptothecin drug and a targeting moiety, wherein the conjugate has a structural formulae selected from the group consisting of MAb-CL1-SN-38, MAb-CL2-SN-38, MAb-CL3-SN-38, MAb-CL4-SN-38, MAb-CL5-SN-38 and having a structure selected from:
- wherein said MAb is selected from the group consisting of a murine, chimeric, primatized, humanized, or human monoclonal antibody, and said antibody is in intact, fragment (Fab, Fab′, F(ab)2, F(ab′)2), or sub-fragment (single-chain construct) form.
Dependencies are inferred from the claim text.